Arbutus Biopharma Corp
NASDAQ:ABUS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Arbutus Biopharma Corp
NASDAQ:ABUS
|
CA |
|
N
|
NICE Holdings Co Ltd
KRX:034310
|
KR |
Intrinsic Value
The intrinsic value of Arbutus Biopharma Corp (ABUS) under the Base Case is 0.388 USD per share.
Compared with the current market price of 4.195 USD, the stock appears
Overvalued by 91% .
The intrinsic value is calculated using the DCF method. The model assumes net margin jumps to 53% in 2026, higher than in any of the last six years, before easing to -314% by 2031. Revenue grows about -52% a year over the next five years, less than a third of its five-year pace of 15%.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Arbutus Biopharma Does
Arbutus Biopharma is a biotechnology company focused on finding treatments for chronic hepatitis B, a liver infection that can become long lasting and serious. It does not sell a broad line of commercial drugs. Instead, it develops experimental medicines and drug-delivery technology, especially programs aimed at shutting down the hepatitis B virus in the body.
- Headquarters
- Canada CA
- Employees
- 19
- IPO date
- Nov 13, 2010
Revenue & Expenses Breakdown
Arbutus Biopharma Corp
Earnings Waterfall
Arbutus Biopharma Corp
The intrinsic value for Arbutus Biopharma Corp (ABUS) under the Base Case is 0.388 USD.
Compared with the current market price of 4.195 USD, the stock appears Overvalued by 91% .